Trial Profile
A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 12 Dec 2023 Primary endpoint has not been met, (The Rate Of Corticosteroid-Requiring cGVHD At One Year From HCT), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 10 Dec 2023 According to Dana-Farber Cancer Institute media release, data from the study will be presented at the 65th American Society of Hematology Annual Meeting and Exposition.